Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues.
about
Tumour necrosis factor-alpha inhibitor-induced hepatic injury in patients with rheumatoid arthritis: two case reports and an analysis of the laboratory data from the Slovenian national biologicals registry.Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics RegisterEffectiveness of anti-tumor necrosis factor agents in the treatment of rheumatoid arthritis: observational studyDrug survival rates of tumor necrosis factor inhibitors in patients with rheumatoid arthritis and ankylosing spondylitis.Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern SwedenSwedish registers to examine drug safety and clinical issues in RA.Adalimumab and methotrexate is more effective than adalimumab alone in patients with established rheumatoid arthritis: results from a 6-month longitudinal, observational, multicentre study.The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study.The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice.Prioritizing the patient: optimizing therapy in rheumatoid arthritis. Results of a patient questionnaire in northern Germany.Using multiple types of studies in systematic reviews of health care interventions--a systematic review.Adverse effects of golimumab in the treatment of rheumatologic diseases.Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis.Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies.Long-term effectiveness and safety of TNF-blocking agents in daily clinical practice: results from the Dutch Rheumatoid Arthritis Monitoring register.Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients.Impact of Tocilizumab Monotherapy on Clinical and Patient-Reported Quality-of-Life Outcomes in Patients with Rheumatoid Arthritis.Costs of drugs for treatment of rheumatic diseases.Drug retention and discontinuation reasons between seven biologics in patients with rheumatoid arthritis -The ANSWER cohort study.
P2860
Q30562413-A9E7A515-BA47-4E37-8E5D-D3033B8F2433Q33726924-ACDC34DB-9699-4352-B0F8-A6E5B440613FQ33932391-16594ECC-4337-4C05-87F6-2B5EF54B5B8AQ34208252-F3BD9D8C-91E6-41B1-A319-96694DF85B37Q35630063-AC675BB1-F486-4076-B914-0A4D0227AEF4Q35637262-BBDE4E6E-81D4-4B4F-B144-4F34317E8825Q35637990-06EE1CAA-7ED4-48AF-8EF7-88DBA5E0C054Q35953468-A83B7B26-EB04-47C2-ADBB-B272DAEEF351Q36204163-D68C7F23-8281-4349-93A7-9933796FC9F9Q37358286-48110FEF-F6D4-4F7D-892B-239F8257D1F2Q37459030-E682B9E5-CC30-400A-914F-F37C9FA9F13CQ38132273-B92BB26E-66E2-42BB-BD21-363D75F09DD4Q40556448-BA33F4F6-D01F-4685-99D4-D0465C9B56E5Q45908921-B9290741-4928-4473-8631-851784F0E095Q45970934-E60E2696-F663-40AE-8D5F-B87782DA9DC1Q46007579-8953194C-A90A-410E-AE46-68D58E91951EQ47132927-03A8A2D7-0E9F-415F-9B71-7CEEBEABD194Q47164070-D5243760-C705-4145-B5A7-EF3EBD3B9B05Q52653996-9DCCB0E8-17C9-46D9-9747-3D48BE61DB62
P2860
Why results of clinical trials and observational studies of antitumour necrosis factor (anti-TNF) therapy differ: methodological and interpretive issues.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Why results of clinical trials ...... gical and interpretive issues.
@ast
Why results of clinical trials ...... gical and interpretive issues.
@en
type
label
Why results of clinical trials ...... gical and interpretive issues.
@ast
Why results of clinical trials ...... gical and interpretive issues.
@en
prefLabel
Why results of clinical trials ...... gical and interpretive issues.
@ast
Why results of clinical trials ...... gical and interpretive issues.
@en
P2093
P2860
P356
P1476
Why results of clinical trials ...... gical and interpretive issues.
@en
P2093
P2860
P304
P356
10.1136/ARD.2004.028530
P407
P478
63 Suppl 2
P577
2004-11-01T00:00:00Z